Bevacizumab Combined with Continuation of EGFR-TKIs in NSCLC Beyond Gradual Progression

Continuation of EGFR-TKI with the combination of bevacizumab is a reasonable strategy in NSCLC patients beyond gradual progression in previous EGFR-TKI treatment. Younger patients with EGFR exon19 deletion mutation may benefit more from the combination therapy.